

Exhibit II

Query: SEQ ID NO: 48

&lt;!--StartFragment--&gt;RESULT 1

ADG89282

ID ADG89282 standard; DNA; 21 BP.

XX

AC ADG89282;

XX

DT 11-MAR-2004 (first entry)

XX

DE Cancer detection method related oligonucleotide #230.

XX

KW ss; cancer; gene expression;

KW estrogen receptor-positive invasive breast cancer.

XX

OS Homo sapiens.

XX

PN WO2003078662-A1.

XX

PD 25-SEP-2003.

XX

PF 12-MAR-2003; 2003WO-US007713.

XX

PR 13-MAR-2002; 2002US-0364890P.

PR 18-SEP-2002; 2002US-0412049P.

XX

PA (GENO-) GENOMIC HEALTH INC.

XX

PI Baker JB, Cronin MT, Kiefer MC, Shak S, Walker MG;

XX

DR WPI; 2003-767536/72.

XX

PT Predicting clinical outcome for a patient diagnosed with cancer comprises

PT determining the expression level of one or more genes, and compared to

PT the amount found in a reference cancer tissue set.

XX

PS Disclosure; SEQ ID NO 230; 198pp; English.

XX

CC The invention relates to a method of predicting clinical outcome for a  
 CC patient diagnosed with cancer by determining the expression level of one  
 CC or more genes, or their expression products, selected from p53BP2,  
 CC cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer  
 CC tissue obtained from the patient, normalized against control gene(s), and  
 CC compared to the amount found in a reference cancer tissue set. The  
 CC specification also discloses an array comprising polynucleotides  
 CC hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-  
 CC 67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3,  
 CC RPS6KB1, Sro, Chk1, ID1, EstR1, p27, CCNBI, XIAP, Chk2, CDC25B, IGFIR,  
 CC AK055699, PI3KC2A, TGFB3, BAG11, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1,  
 CC HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENTI, EPHXI, IFIA,  
 CC CDHI, HIF1t, IGFBP3, CTSB, Her2 and DIABLO, immobilized on a solid  
 CC surface. The methods are useful for predicting clinical outcome for a  
 CC patient diagnosed with cancer, classifying cancer, and predicting the  
 CC likelihood of long-term survival of a breast cancer patient, or a patient  
 CC diagnosed with invasive breast cancer or with estrogen receptor (ER)-  
 CC positive invasive breast cancer. This sequence corresponds to an  
 CC oligonucleotide used in the method of the invention.

XX

SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 100.0%; Score 21; DB 10; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1  GCCGAGGCTTTTCTACCAGAA 21
            |||
Db          1  GCCGAGGCTTTTCTACCAGAA 21
<!--EndFragment-->
```